News
MYC targeting by OMO-103 in solid tumors: a phase 1 trial
Peptomyc presents results of their Ph1 study of OMO-103 in advanced solid tumours. OMO-103 is an inhibitor for MYC, one of the most wanted, long-considered,
Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial
Peptomyc is proud to announce that the results of the MYCure clinical trial have just been published in Nature Medicine (https://www.nature.com/articles/s41591-024-02805-1), demonstrating the unique potential
binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io
binx health, a healthcare technology and diagnostics company focused on expanding Sexually Transmitted Infection testing at the Point-of-Care, announced a national distribution agreement with Cardinal
binx health Expands Nationwide Distribution of the binx io Molecular Point-of-Care Platform
binx health announced today it has entered into a non-exclusive national distribution agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to expand the
InBrain Neuroelectronics wins FDA breakthrough nod for intelligent network modulation system
InBrain Neuroelectronics announced today that it received FDA breakthrough device designation for its intelligent network modulation system. Read more
Aliath Bioventures appoints Dr Philippe Monteyne and announces additional hires to further strengthen its Life Sciences Impact business
Aliath Bioventures, the healthcare impact investment platform of AltamarCAM Partners, appoints Philippe Monteyne, MD, PhD as a new Partner to reinforce the company’s healthcare investment
